immunohistochemical staining of precursor forms of prostate-specific antigen (propsa) in metastatic...
TRANSCRIPT
![Page 1: Immunohistochemical Staining of Precursor Forms of Prostate-specific Antigen (proPSA) in Metastatic Prostate Cancer Anil V. Parwani, MD, PhD,* Cameron](https://reader036.vdocuments.us/reader036/viewer/2022062322/56649eaa5503460f94baec86/html5/thumbnails/1.jpg)
Immunohistochemical Staining of Precursor FormsImmunohistochemical Staining of Precursor Formsof Prostate-specific Antigen (proPSA) in Metastaticof Prostate-specific Antigen (proPSA) in Metastatic
Prostate CancerProstate Cancer
Anil V. Parwani, MD, PhD,* Cameron Marlow, BS, Angelo M. DAnil V. Parwani, MD, PhD,* Cameron Marlow, BS, Angelo M. Demarzo, MD, PhD, Stephen D. Mikolajczyk, PhD, Harry G. Rittemarzo, MD, PhD, Stephen D. Mikolajczyk, PhD, Harry G. Ritt
enhouse, PhD, Robert W. Veltri, MD, and Theresa Y. Chanenhouse, PhD, Robert W. Veltri, MD, and Theresa Y. Chan Am J Surg Pathol 2006;30:1231–1236
指導老師 : 陳志榮老師 報告者 :Intern 陳嘉哲
![Page 2: Immunohistochemical Staining of Precursor Forms of Prostate-specific Antigen (proPSA) in Metastatic Prostate Cancer Anil V. Parwani, MD, PhD,* Cameron](https://reader036.vdocuments.us/reader036/viewer/2022062322/56649eaa5503460f94baec86/html5/thumbnails/2.jpg)
Introduction Introduction
Prostate carcinoma: * most common carcinoma in American
man. * second leading cancer-related deaths i
n the United States. * In the year 2005 in the United States 230,000 new cases of prostate cancer 230,000 new cases of prostate cancer 30,000 deaths due to prostate cancer30,000 deaths due to prostate cancer
![Page 3: Immunohistochemical Staining of Precursor Forms of Prostate-specific Antigen (proPSA) in Metastatic Prostate Cancer Anil V. Parwani, MD, PhD,* Cameron](https://reader036.vdocuments.us/reader036/viewer/2022062322/56649eaa5503460f94baec86/html5/thumbnails/3.jpg)
Introduction Introduction
Prostate-specific antigen (PSA) * As a tumor marker for prostate cancer* a serine protease produced by both pr
ostate epithelial and cancer cells.* normal function: liquify gelatinous sem
en after ejaculation, allowing spermatazoa to more easily "swim" through the uterine cervix.
![Page 4: Immunohistochemical Staining of Precursor Forms of Prostate-specific Antigen (proPSA) in Metastatic Prostate Cancer Anil V. Parwani, MD, PhD,* Cameron](https://reader036.vdocuments.us/reader036/viewer/2022062322/56649eaa5503460f94baec86/html5/thumbnails/4.jpg)
Introduction Introduction
Precursors of prostate-specific antigens: Precursors of prostate-specific antigens: * * 244-amino acid proenzyme244-amino acid proenzyme * * more concentrated in prostate cancer more concentrated in prostate cancer
than in benign tissuethan in benign tissue * * a more cancer-specific markera more cancer-specific marker
![Page 5: Immunohistochemical Staining of Precursor Forms of Prostate-specific Antigen (proPSA) in Metastatic Prostate Cancer Anil V. Parwani, MD, PhD,* Cameron](https://reader036.vdocuments.us/reader036/viewer/2022062322/56649eaa5503460f94baec86/html5/thumbnails/5.jpg)
Introduction Introduction Authors’ previous studies: Authors’ previous studies: ** Immunohistochemical staining (IHS) :Immunohistochemical staining (IHS) :
monoclonal antibodies (mABs) against proPSA with a truncated proleader peptide containing 2 amino acids ([-2]pPSA), and against native proPSA ([-5/-7]pPSA). 2 aa = serine, arginine
* mABs to proPSA are specific for benign and malignant prostatic tissue.
![Page 6: Immunohistochemical Staining of Precursor Forms of Prostate-specific Antigen (proPSA) in Metastatic Prostate Cancer Anil V. Parwani, MD, PhD,* Cameron](https://reader036.vdocuments.us/reader036/viewer/2022062322/56649eaa5503460f94baec86/html5/thumbnails/6.jpg)
Introduction Introduction
* ProPSA remained uniform among the different tumor grade.
* PSA staining intensities and Gleason score
had a strong inverse correlation.* Metastatic prostate carcinoma may sho
w negative PSA staining.
![Page 7: Immunohistochemical Staining of Precursor Forms of Prostate-specific Antigen (proPSA) in Metastatic Prostate Cancer Anil V. Parwani, MD, PhD,* Cameron](https://reader036.vdocuments.us/reader036/viewer/2022062322/56649eaa5503460f94baec86/html5/thumbnails/7.jpg)
IntroductionIntroduction
The objective of this study:* compare the IHS patterns of proPSA wit
h that of PSA and prostatic acid phosphate (PAP) on a series of metastatic prostate carcinoma cases.
* Find the utility of proPSA in these lesion
![Page 8: Immunohistochemical Staining of Precursor Forms of Prostate-specific Antigen (proPSA) in Metastatic Prostate Cancer Anil V. Parwani, MD, PhD,* Cameron](https://reader036.vdocuments.us/reader036/viewer/2022062322/56649eaa5503460f94baec86/html5/thumbnails/8.jpg)
Materials and MethodsMaterials and Methods
Tissue Microarray (TMA) Design:Tissue Microarray (TMA) Design:* * 74 cases( metastatic prostate carcinoma):74 cases( metastatic prostate carcinoma): Soft tissue / bone N= 40 Soft tissue / bone N= 40 lymph node N= 34 lymph node N= 34 from the surgical pathology files of The
Johns Hopkins Hospital. (nonhormone refractory tumors)
* 3 cores of each specimen - TMA
![Page 9: Immunohistochemical Staining of Precursor Forms of Prostate-specific Antigen (proPSA) in Metastatic Prostate Cancer Anil V. Parwani, MD, PhD,* Cameron](https://reader036.vdocuments.us/reader036/viewer/2022062322/56649eaa5503460f94baec86/html5/thumbnails/9.jpg)
Tissue Microarray (TMA) DesigTissue Microarray (TMA) Designn
All the metastatic tumors: higher grade, poorly differentiated carcinomas.
Control tissues:* primary prostate adenocarcinoma with G
leason scores ranging from 6 to 7 (n=20)* normal prostatic tissue (n=20)* normal tissue from brain, skin, colon, and
other 14 tissues to the TMA.
![Page 10: Immunohistochemical Staining of Precursor Forms of Prostate-specific Antigen (proPSA) in Metastatic Prostate Cancer Anil V. Parwani, MD, PhD,* Cameron](https://reader036.vdocuments.us/reader036/viewer/2022062322/56649eaa5503460f94baec86/html5/thumbnails/10.jpg)
Immunohistochemistry
IHS: IHS: deparaffinized TMA slides using a standard streptavidin horseradish-peroxidase conjugate.
A purified mouse immunoglobulin G mAB, PS2P446 proPSA with both the 7 aa and 5 aa leader peptides ([-5/-7]pPSA, Beckman Coulter, San Diego, CA).
![Page 11: Immunohistochemical Staining of Precursor Forms of Prostate-specific Antigen (proPSA) in Metastatic Prostate Cancer Anil V. Parwani, MD, PhD,* Cameron](https://reader036.vdocuments.us/reader036/viewer/2022062322/56649eaa5503460f94baec86/html5/thumbnails/11.jpg)
Immunohistochemistry
A purified mouse immunoglobulin G mAB, PS2373.3, which recognizes proPSA with a 2 aa leader peptide ([-2]pPSA, Beckman Coulter). pPSA form
These proPSA mABs had less than 0.2% cross-reactivity to PSA or to each other.
These proPSA mABs: research use.
![Page 12: Immunohistochemical Staining of Precursor Forms of Prostate-specific Antigen (proPSA) in Metastatic Prostate Cancer Anil V. Parwani, MD, PhD,* Cameron](https://reader036.vdocuments.us/reader036/viewer/2022062322/56649eaa5503460f94baec86/html5/thumbnails/12.jpg)
Immunohistochemistry Evaluation of metastatic prostate carcinEvaluation of metastatic prostate carcin
omas: intensity and extent of IHS. omas: intensity and extent of IHS. ** cocontrolled by human eyentrolled by human eye
The intensity of staining was categorized as weak, moderate, or strong.
A numerical score assigned to each spot on the TMA.
0 for negative ; 1 for weak ; 2 for moderate ; 3 for strong
![Page 13: Immunohistochemical Staining of Precursor Forms of Prostate-specific Antigen (proPSA) in Metastatic Prostate Cancer Anil V. Parwani, MD, PhD,* Cameron](https://reader036.vdocuments.us/reader036/viewer/2022062322/56649eaa5503460f94baec86/html5/thumbnails/13.jpg)
Immunohistochemistry
a mean score was calculated for each sample present in triplicate.
The mean score : 0 to 0.5 = negative ; 0.5 to 1.5= weak, 1.5 to 2.5 = moderate ; 2.5 or greater = strong.
![Page 14: Immunohistochemical Staining of Precursor Forms of Prostate-specific Antigen (proPSA) in Metastatic Prostate Cancer Anil V. Parwani, MD, PhD,* Cameron](https://reader036.vdocuments.us/reader036/viewer/2022062322/56649eaa5503460f94baec86/html5/thumbnails/14.jpg)
Immunohistochemistry Extent of staining: Extent of staining: diffuse ( more than 50% of cells)diffuse ( more than 50% of cells) patchy ( less than 50% of cells)patchy ( less than 50% of cells) 5 cases : 5 cases : insufficient tissue on more than 2 of t
he 3 spots can’t be evaluated. 9 cases : lack of tissue on PSA and PAP stains
only ProPSA. Total 60 cases all 4 mABs were evaluated.
![Page 15: Immunohistochemical Staining of Precursor Forms of Prostate-specific Antigen (proPSA) in Metastatic Prostate Cancer Anil V. Parwani, MD, PhD,* Cameron](https://reader036.vdocuments.us/reader036/viewer/2022062322/56649eaa5503460f94baec86/html5/thumbnails/15.jpg)
Results Results
![Page 16: Immunohistochemical Staining of Precursor Forms of Prostate-specific Antigen (proPSA) in Metastatic Prostate Cancer Anil V. Parwani, MD, PhD,* Cameron](https://reader036.vdocuments.us/reader036/viewer/2022062322/56649eaa5503460f94baec86/html5/thumbnails/16.jpg)
ResultsResults
There were minor differences between the
4 antibodies in extent of staining. * [-5/-7]pPSA and PSA : the most numb
er of cases with diffuse staining (75%, 69%), the least number of cases with patchy staining (25% and 31%).
![Page 17: Immunohistochemical Staining of Precursor Forms of Prostate-specific Antigen (proPSA) in Metastatic Prostate Cancer Anil V. Parwani, MD, PhD,* Cameron](https://reader036.vdocuments.us/reader036/viewer/2022062322/56649eaa5503460f94baec86/html5/thumbnails/17.jpg)
ResultsResults
![Page 18: Immunohistochemical Staining of Precursor Forms of Prostate-specific Antigen (proPSA) in Metastatic Prostate Cancer Anil V. Parwani, MD, PhD,* Cameron](https://reader036.vdocuments.us/reader036/viewer/2022062322/56649eaa5503460f94baec86/html5/thumbnails/18.jpg)
[-5/-7]pPSA showed the most number of positive cases (98%) compared with [-2] pPSA (80%), PSA (81%), PAP (83%).
![Page 19: Immunohistochemical Staining of Precursor Forms of Prostate-specific Antigen (proPSA) in Metastatic Prostate Cancer Anil V. Parwani, MD, PhD,* Cameron](https://reader036.vdocuments.us/reader036/viewer/2022062322/56649eaa5503460f94baec86/html5/thumbnails/19.jpg)
strong or moderate staining was seen in 82%, [-5/-7] pPSA, 76% PSA, 39% PAP, and 29% [-2] pPSA.
![Page 20: Immunohistochemical Staining of Precursor Forms of Prostate-specific Antigen (proPSA) in Metastatic Prostate Cancer Anil V. Parwani, MD, PhD,* Cameron](https://reader036.vdocuments.us/reader036/viewer/2022062322/56649eaa5503460f94baec86/html5/thumbnails/20.jpg)
Seven cases (12%) were negative for both PSA and PAP, but showed staining with [-5/-7]pPSA and/or [-2]pPSA.
![Page 21: Immunohistochemical Staining of Precursor Forms of Prostate-specific Antigen (proPSA) in Metastatic Prostate Cancer Anil V. Parwani, MD, PhD,* Cameron](https://reader036.vdocuments.us/reader036/viewer/2022062322/56649eaa5503460f94baec86/html5/thumbnails/21.jpg)
Result Result
Only 3 case (5%): Only 3 case (5%): [-5/-7]pPSA was the only positive marker; 2 moderate, and 1 weak.
Only 1 case (2%): [-2]pPSA was the only positive marker; the intensity of this one weak.
![Page 22: Immunohistochemical Staining of Precursor Forms of Prostate-specific Antigen (proPSA) in Metastatic Prostate Cancer Anil V. Parwani, MD, PhD,* Cameron](https://reader036.vdocuments.us/reader036/viewer/2022062322/56649eaa5503460f94baec86/html5/thumbnails/22.jpg)
ResultResult
There was no staining in prostatic stromal and vascular tissue.
No other tumor types was in this study. Only focal weak cytoplasmic staining wit
h both the proPSA mABs to control thyroid and kidney tissues.
![Page 23: Immunohistochemical Staining of Precursor Forms of Prostate-specific Antigen (proPSA) in Metastatic Prostate Cancer Anil V. Parwani, MD, PhD,* Cameron](https://reader036.vdocuments.us/reader036/viewer/2022062322/56649eaa5503460f94baec86/html5/thumbnails/23.jpg)
Discussion Discussion
In this article, authors evaluated: proPSA as a diagnostic markers in the detectio
n of metastatic prostatic adenocarcinoma versus PSA and PAP.
PSA shows a decrease in expression from benign epithelium to HGPIN and adenocarcinoma.
(Urology 49: 857–862, 1997.)
![Page 24: Immunohistochemical Staining of Precursor Forms of Prostate-specific Antigen (proPSA) in Metastatic Prostate Cancer Anil V. Parwani, MD, PhD,* Cameron](https://reader036.vdocuments.us/reader036/viewer/2022062322/56649eaa5503460f94baec86/html5/thumbnails/24.jpg)
Discussion Discussion
A strong inverse correlation between PSA staining intensities and Gleason scores.
(Am J Clin Pathol 117: 471–477, 2002.) The immunoreactivity for pro-PSA appears to r
emain uniform among the different tumor grades.
[-2] proPSA appeared to be preferentially more concentrated in cancer tissue than in benign glands. (Urology. 2003;62:177–181.)
![Page 25: Immunohistochemical Staining of Precursor Forms of Prostate-specific Antigen (proPSA) in Metastatic Prostate Cancer Anil V. Parwani, MD, PhD,* Cameron](https://reader036.vdocuments.us/reader036/viewer/2022062322/56649eaa5503460f94baec86/html5/thumbnails/25.jpg)
Discussion Discussion
In current study, no difference in the staiIn current study, no difference in the staining pattern of benign gland for 4mABs.ning pattern of benign gland for 4mABs.
In this study, In this study, proPSA [-5/-7] showed the most number of cases with moderate or strong staining (76%) as compared with PSA (56%), PAP (43%) and proPSA [-2] (55%).
![Page 26: Immunohistochemical Staining of Precursor Forms of Prostate-specific Antigen (proPSA) in Metastatic Prostate Cancer Anil V. Parwani, MD, PhD,* Cameron](https://reader036.vdocuments.us/reader036/viewer/2022062322/56649eaa5503460f94baec86/html5/thumbnails/26.jpg)
Discussion Discussion
a case of poorly differentiated carcinoma from an unknown primary. using PSA or PAP as a diagnostic marker?
In this study, -5/-7 proPSA (native proPSA) may be a better marker than PSA and PAP in metastatic prostate adenocarcinoma,
only 2 cases (3%) being negative for the marker.
![Page 27: Immunohistochemical Staining of Precursor Forms of Prostate-specific Antigen (proPSA) in Metastatic Prostate Cancer Anil V. Parwani, MD, PhD,* Cameron](https://reader036.vdocuments.us/reader036/viewer/2022062322/56649eaa5503460f94baec86/html5/thumbnails/27.jpg)
Discussion Discussion
PSA is a serine protease, and a major protein in seminal fluid.
PSA is produced by both prostate epithelial cells and prostate cancer and is secreted into prostatic ducts as an inactive 244-amino acid proenzyme (proPSA) which is activated by cleavage of 7 N-terminal amino acids.
(Cancer. 2004;101:894–904.)
![Page 28: Immunohistochemical Staining of Precursor Forms of Prostate-specific Antigen (proPSA) in Metastatic Prostate Cancer Anil V. Parwani, MD, PhD,* Cameron](https://reader036.vdocuments.us/reader036/viewer/2022062322/56649eaa5503460f94baec86/html5/thumbnails/28.jpg)
Discussion Discussion
PSA either as the free “non-complexed” form or as a complex with alpha1-antichymotrypsin.
Ratio of free to total serum PSA * lower percent free PSA levels correlatin
g with a higher risk of prostate cancer. (JAMA 297: 1542–1547, 1998)
![Page 29: Immunohistochemical Staining of Precursor Forms of Prostate-specific Antigen (proPSA) in Metastatic Prostate Cancer Anil V. Parwani, MD, PhD,* Cameron](https://reader036.vdocuments.us/reader036/viewer/2022062322/56649eaa5503460f94baec86/html5/thumbnails/29.jpg)
Discussion Discussion
Normally proPSA with a seven amino acid (aa) proleader peptide ([-7]pPSA).
Pro PSA (pPSA), precursor form of PSA, is a component of free PSA in the serum of PCa patients.
ProPSA is differentially elevated in PZ-C, but is largely undetectable in TZ .
(Cancer Res 60: 756–769, 2000.)
![Page 30: Immunohistochemical Staining of Precursor Forms of Prostate-specific Antigen (proPSA) in Metastatic Prostate Cancer Anil V. Parwani, MD, PhD,* Cameron](https://reader036.vdocuments.us/reader036/viewer/2022062322/56649eaa5503460f94baec86/html5/thumbnails/30.jpg)
Discussion Discussion
ProPSA: ↑ specificity for prostate carcinoma, particularly in the 2 to 4 ng/mL PSA range. (J Urol. 2003;170:2181–2185)
Catalona et al indicated:1. Percent proPSA better than percent free and c
alculated complexed PSA for detecting prostate carcinoma in the PSA range of 2 to 10 ng/mL.
2. Selectivity for detecting more aggressive cancers (Gleason score 7 or greater and/or extracapsular tumor extension.) (J Urol. 2004; 71:2239–2244.)
![Page 31: Immunohistochemical Staining of Precursor Forms of Prostate-specific Antigen (proPSA) in Metastatic Prostate Cancer Anil V. Parwani, MD, PhD,* Cameron](https://reader036.vdocuments.us/reader036/viewer/2022062322/56649eaa5503460f94baec86/html5/thumbnails/31.jpg)
Discussion Discussion
In the diagnostic range of 4 to 10 ng/mL, PSA has limited specificity for distinguishing early prostatic adenocarcinoma from benign prostatic hyperplasia. (Cancer. 2004;101:894–904.)
![Page 32: Immunohistochemical Staining of Precursor Forms of Prostate-specific Antigen (proPSA) in Metastatic Prostate Cancer Anil V. Parwani, MD, PhD,* Cameron](https://reader036.vdocuments.us/reader036/viewer/2022062322/56649eaa5503460f94baec86/html5/thumbnails/32.jpg)
Discussion Discussion
Further ideas: use of proPSA as an immuFurther ideas: use of proPSA as an immunohistochemical marker in amount of spnohistochemical marker in amount of specimens from variety of sources includinecimens from variety of sources including cytology specimen.g cytology specimen.
![Page 33: Immunohistochemical Staining of Precursor Forms of Prostate-specific Antigen (proPSA) in Metastatic Prostate Cancer Anil V. Parwani, MD, PhD,* Cameron](https://reader036.vdocuments.us/reader036/viewer/2022062322/56649eaa5503460f94baec86/html5/thumbnails/33.jpg)
A Truncated Precursor Form of Prostate-specific Antigen Is a More Specific Serum Marker of Prostate Cancer
(CANCER RESEARCH 61, 6958–6963, September 15, 2001)
![Page 34: Immunohistochemical Staining of Precursor Forms of Prostate-specific Antigen (proPSA) in Metastatic Prostate Cancer Anil V. Parwani, MD, PhD,* Cameron](https://reader036.vdocuments.us/reader036/viewer/2022062322/56649eaa5503460f94baec86/html5/thumbnails/34.jpg)
HK2 and trypsin can activate [-5/-7]pPSA to mature PSA
![Page 35: Immunohistochemical Staining of Precursor Forms of Prostate-specific Antigen (proPSA) in Metastatic Prostate Cancer Anil V. Parwani, MD, PhD,* Cameron](https://reader036.vdocuments.us/reader036/viewer/2022062322/56649eaa5503460f94baec86/html5/thumbnails/35.jpg)
UROLOGY 62: 177–181, 2003. © 2003
![Page 36: Immunohistochemical Staining of Precursor Forms of Prostate-specific Antigen (proPSA) in Metastatic Prostate Cancer Anil V. Parwani, MD, PhD,* Cameron](https://reader036.vdocuments.us/reader036/viewer/2022062322/56649eaa5503460f94baec86/html5/thumbnails/36.jpg)
UROLOGY 62: 177–181, 2003. © 2003
![Page 37: Immunohistochemical Staining of Precursor Forms of Prostate-specific Antigen (proPSA) in Metastatic Prostate Cancer Anil V. Parwani, MD, PhD,* Cameron](https://reader036.vdocuments.us/reader036/viewer/2022062322/56649eaa5503460f94baec86/html5/thumbnails/37.jpg)
SERUM PRO-PROSTATE SPECIFIC ANTIGEN PREFERENTIALLYDETECTS AGGRESSIVE PROSTATE CANCERS IN MEN WITH
2 TO 4 NG/ML PROSTATE SPECIFIC ANTIGEN
Urology Vol. 171, 2239–2244, June 2004
![Page 38: Immunohistochemical Staining of Precursor Forms of Prostate-specific Antigen (proPSA) in Metastatic Prostate Cancer Anil V. Parwani, MD, PhD,* Cameron](https://reader036.vdocuments.us/reader036/viewer/2022062322/56649eaa5503460f94baec86/html5/thumbnails/38.jpg)
Discussion Discussion
Why does proPSA show greater staining Why does proPSA show greater staining than than [-2] proPSA in metastatic cancer?
Why should we find a better diagnostic marker for malignant prostate cancer?
Maybe we can evaluate proPSA in the serum to detect prostate cancer.
![Page 39: Immunohistochemical Staining of Precursor Forms of Prostate-specific Antigen (proPSA) in Metastatic Prostate Cancer Anil V. Parwani, MD, PhD,* Cameron](https://reader036.vdocuments.us/reader036/viewer/2022062322/56649eaa5503460f94baec86/html5/thumbnails/39.jpg)